Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Avacopan in Patients with C3 Glomerulopathy
2017-001821-42Phase 2Unknown
- Sponsor
- ChemoCentryx
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Complement 3 glomerulopathy (C3G), dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) comparing Avacopan with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
avacopan
03
Conditions
Complement 3 glomerulopathy (C3G)dense deposit disease (DDD)C3 glomerulonephritis (C3GN)
Beyond the preview
Go deeper on 2017-001821-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001821-42.